[43] confirmed that NPAS2 played a tumour‐promoting gene in hepatocellular carcinoma (HCC) and upregulated NPAS2 was associated with aggressive clinical problems and poor prognosis, which was consistent with its role in acute myeloid leukaemia [44]. Here, NPAS2 is linked to acute myeloid leukemia.